Caffeine and adenosine A2A receptor inactivation decrease striatal neuropathology in a lentiviral‐based model of Machado–Joseph disease
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Objective: Machado–Joseph disease (MJD) is a neurodegenerative disorder associated with an abnormal CAG expansion, which translates into an expanded polyglutamine tract within ataxin‐3. There is no therapy to prevent or modify disease progression. Because caffeine (a nonselective adenosine receptor antagonist) and selective adenosine A 2A receptor (A 2A R) blockade alleviate neurodegeneration in different brain diseases, namely at early stages of another polyglutamine‐related disorder such as Huntington's disease, we now tested their ability to control MJD‐associated neurodegeneration. Methods: MJD was modeled by transducing the striatum of male adult C57Bl/6 mice with lentiviral vectors encoding mutant ataxin‐3 in one hemisphere and wild‐type ataxin‐3 in the other hemisphere (as internal control). Caffeine (1g/L) was applied through the drinking water. Mice were killed at different time points (from 2 to 12 weeks) to probe for the appearance of different morphological changes using immunohistochemical analysis. Results: Mutant ataxin‐3 caused an evolving neuronal dysfunction (loss of DARPP‐32 staining) leading to neurodegeneration (cresyl violet and neuronal nuclei staining) associated with increased number of mutant ataxin‐3 inclusions in the basal ganglia. Notably, mutant ataxin‐3 triggered early synaptotoxicity (decreased synaptophysin and microtubule‐associated protein‐2 staining) and reactive gliosis (glial fibrillary acidic protein and CD11b staining), which predated neuronal dysfunction and damage. Caffeine reduced the appearance of all these morphological modifications, which were also abrogated in mice with a global A 2A R inactivation (knockout). Interpretation: Our findings provide a demonstration that synaptotoxicity and gliosis are precocious events in MJD and that caffeine and A 2A R inactivation decrease MJD‐associated striatal pathology, which paves the way to consider A 2A Rs as novel therapeutic targets to manage MJD. Ann Neurol 2013;73:655–666
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fredholm, B. B., Bättig, K., Holmén, J., Nehlig, A., & Zvartau, E. E. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01396-6 · Cited by 2,624
Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death
Arrasate, M., Mitra, S., Schweitzer, E. S., Segal, M. R., & Finkbeiner, S. (2004) · Nature · doi:10.1038/nature02998 · Cited by 1,979
Lee, J. W., Lee, Y. K., Yuk, D. Y., Choi, D. Y., Ban, S. B., Oh, K. W., & Hong, J. T. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-37 · Cited by 772
An Update on the Mechanisms of the Psychostimulant Effects of Caffeine
Ferré, S. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05196.x · Cited by 440
Adenosine receptors and brain diseases: neuroprotection and neurodegeneration
Gomes, C. V., Kaster, M. P., Tomé, A. R., Agostinho, P. M., & Cunha, R. A. (2011) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2010.12.001 · Cited by 419 · cited 3×
“Caffeine and A2AR blockade afford robust neuroprotection in different neurodegenerative disorders, in accordance with the key role of A2ARs in controlling synaptic viability, apoptotic neuronal death, astrocytic function, and neuroinflammation.(23,24) In particular, in Huntington’s disease, another polyQ disorder, A2A…”
BackgroundSelf-citationRebola, N., Lujan, R., Cunha, R. A., & Mulle, C. (2008) · Neuron · doi:10.1016/j.neuron.2007.11.023 · Cited by 376
Self-citationA focus on the synapse for neuroprotection in Alzheimer disease and other dementias
Coleman, P., Federoff, H., & Kurlan, R. (2004) · Neurology · doi:10.1212/01.wnl.0000140626.48118.0a · Cited by 314
Caffeine, Adenosine Receptors, and Synaptic Plasticity
Costenla, A. R., Cunha, R. A., & de Mendonça, A. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-091384 · Cited by 132
Self-citationDuarte, J. M. N., Agostinho, P. M., Carvalho, R. A., & Cunha, R. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0021899 · Cited by 130 · cited 1×
“minimum period of 2 weeks is required to allow a metabolic stabilization after beginning the free access to caffeine drinking.(29,31)”
BackgroundSelf-citation
Cited by
How does adenosine control neuronal dysfunction and neurodegeneration?
Cunha, R. A. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13724 · Cited by 441
Self-citationThe neuroprotective effects of caffeine in neurodegenerative diseases
Kolahdouzan, M., & Hamadeh, M. J. (2017) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12684 · Cited by 302
ATP as a multi-target danger signal in the brain
Rodrigues, R. J., Tomé, A. R., & Cunha, R. A. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00148 · Cited by 259
Self-citationCunha-Santos, J., Duarte-Neves, J., Carmona, V., Guarente, L., Pereira de Almeida, L., & Cavadas, C. (2016) · Nature Communications · doi:10.1038/ncomms11445 · Cited by 109
Madeira, M. H., Boia, R., Elvas, F., Martins, T., Cunha, R. A., Ambrósio, A. F., & Santiago, A. R. (2016) · Translational Research · doi:10.1016/j.trsl.2015.11.005 · Cited by 83
Self-citation
Metadata
- Authors
- Gonçalves, N., Simões, A. T., Cunha, R. A., & de Almeida, L. P.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2013-04-26
- Volume
- 73
- Issue
- 5
- Pages
- 655-666
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2124702644
- Cited by
- 87
- References
- 9
- FWCI
- 3.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.